MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE

MODIFIED ANTI-PD-L1 ANTIBODIES AND METHODS AND USES FOR TREATING A NEURODEGENERATIVE DISEASE

The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that emp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: KROGH, Berit Olsen, JENSEN, Allan, EISENBACH-SCHWARTZ, Michal, YOLES, Ester, EGEBJERG, Jan, DAVID, Carol, BARUCH, Kuti
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present specification discloses anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.